Posted by rob on November 29, 2004 under Uncategorized | 
- Results Will Be Presented Dec. 5 at Annual American Society
of Hematology Conference -
WHITE PLAINS, N.Y., NOV. 29 /PRNewswire/ — Alan Kinniburgh, Senior Vice
President for Research for The Leukemia & Lymphoma Society, is available to
discuss clinical findings showing the overwhelming success of a new drug,
BMS-354825, in overcoming resistance to Gleevec, the frontline therapy for
chronic myelogenous leukemia.
Dr. Kinniburgh will be available at the American Society of Hematology
conference in San Diego on Sunday, Dec. 5, when the findings of the Phase I
clinical trial will be presented by Charles Sawyers, M.D., the lead
investigator of the team.
The Leukemia & Lymphoma Society led the way in funding the research that
led up to this clinical trial, with a $7.5 million Specialized Center of
Research (SCOR) grant over a 5-year period.
To arrange an interview with Dr. Kinniburgh, contact him on his cell phone
at 914-837-6650, or contact Jennifer Corrigan at 732-382-8898 (office), or
732-742-7148 (cell).
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=109&STORY=/www/story/11-29-2004/0002550970&EDATE=
Posted by rob on under Uncategorized |
Researchers at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), have found that inhibition of the same protein produces different effects in mouse cell lines depending on whether those cell lines express normal or cancerous forms of Kit, a cell surface receptor critical for the development of some kinds of blood cells. These findings, appearing in the journal Blood online*, November 2004, reveal a potential new target for treating certain blood cell disorders.
From U.S. NIH:
Protein Plays Different Roles in Growth of Normal and Cancerous Mouse Cell Lines
Researchers at the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), have found that inhibition of the same protein produces different effects in mouse cell lines depending on whether those cell lines express normal or cancerous forms of Kit, a cell surface receptor critical for the development of some kinds of blood cells. These findings, appearing in the journal Blood online*, November 2004, reveal a potential new target for treating certain blood cell disorders.
A specific mutation affecting the catalytic domain of the Kit receptor results in a cancerous form of Kit found in patients with mast cell disease and some forms of acute myeloid leukemia. This particular Kit mutant, known as D814Y, is resistant to Gleevecâ?¢, a drug used to treat a variety of diseases associated with Kit and related proteins. Other types of cancer, including gastrointestinal stromal cell tumors, have different Kit mutations that are sensitive to Gleevec. One potential way to circumvent the Gleevec-resistant form of Kit is to target one or more of the proteins that are activated by Kit.
NCI researchers Diana Linnekin, Ph.D., and Tanya Jelacic, Ph.D., found that inhibition of one such Kit-activated protein, PKCδ (a member of a family of protein kinases involved in cell signaling), reduced the growth of a mouse mast cell line expressing the D814Y mutant Kit by approximately 40 percent. In contrast, PKCδ inhibition did not suppress the growth of normal mast cells. ”This is the first demonstration of a function change in PKCδ resulting from a cancerous mutation in a growth factor receptor,” said Linnekin.
Because anti-PKCδ drugs would specifically inhibit the growth of mutated cells and not affect normal ones, these results suggest that PKCδ may be a therapeutic target for mast cell disease associated with the D814Y mutation in Kit and possibly for other disorders associated with Kit catalytic domain mutations. ”This work is a promising study on cancer inhibition,” said Linnekin. ”Dr. Jelacic and I believe that follow-up work with human cell lines, as well as work in mouse models of cancer, would be definitely worthwhile.”
http://www.scienceblog.com/community/article4767.html
Posted by rob on under Uncategorized |
Post Details
Title: Pic Of The Day
Date: 11/28/2004 9:12:17 PM
A supporter of Ukrainian opposition leader Viktor Yushchenko holds a rose during a rally in Kiev.
Posted by rob on under Uncategorized |
A supporter of Ukrainian opposition leader Viktor Yushchenko holds a rose during a rally in Kiev.
